button bars forest bayes pooled summary circles
 
pCR

es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)

versus paclitaxel followed by doxorubicin plus cyclophosphamide
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide vs. paclitaxel followed by doxorubicin plus cyclophosphamide 1 certainty unassessable+272%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons